Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Valneva SE Pref.

Market Cap 434M 503M 400M 374M 702M 47.71B 710M 4.73B 1.84B 23.22B 1.88B 1.84B 80.36B P/E Ratio 2026 *
-6.23x
P/E Ratio 2027 * 6.02x
Enterprise Value 562M 651M 518M 485M 909M 61.79B 919M 6.13B 2.38B 30.08B 2.44B 2.39B 104B EV / Sales 2026 *
3.7x
EV / Sales 2027 * 1.68x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 2021-07-28
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 2023-12-19
Director/Board Member 75 2013-03-06
Chairman 65 2023-12-19
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 502M
-0.35%+0.97%-13.80%-13.25% 43.03B
+3.11%+3.11%+279.08%+501.52% 32.71B
+0.22%-1.08%+15.66%-15.65% 30.29B
+1.62%-2.08%-1.91%+24.64% 29.4B
+4.09%+0.93%+12.97%+20.22% 25.08B
+1.14%+3.62% - - 13.54B
-1.63%+2.88%+56.69%+113.41% 13.35B
-0.40%-1.29%+6.23%+7.63% 12.97B
-0.74%-1.62%+105.89%+74.92% 12.11B
Average +0.71%+1.45%+57.60%+89.18% 23.61B
Weighted average by Cap. +1.05%+1.48%+57.30%+96.08%

Financials

2026 *2027 *
Net sales 152M 176M 140M 131M 246M 16.71B 249M 1.66B 644M 8.13B 659M 645M 28.14B 294M 341M 271M 254M 476M 32.36B 481M 3.21B 1.25B 15.75B 1.28B 1.25B 54.5B
Net income -66.01M -76.58M -60.84M -57M -107M -7.26B -108M -720M -280M -3.54B -287M -280M -12.24B 70.5M 81.79M 64.98M 60.87M 114M 7.76B 115M 769M 299M 3.78B 306M 299M 13.07B
Net Debt 128M 149M 118M 111M 207M 14.09B 210M 1.4B 543M 6.86B 556M 544M 23.73B 60.02M 69.63M 55.32M 51.82M 97.19M 6.6B 98.25M 655M 255M 3.21B 260M 255M 11.12B
Logo Valneva SE Pref.
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.286EUR
Average target price
5.233EUR
Spread / Average Target
+128.93%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!